202 related articles for article (PubMed ID: 29884901)
1. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
Barghout SH; Patel PS; Wang X; Xu GW; Kavanagh S; Halgas O; Zarabi SF; Gronda M; Hurren R; Jeyaraju DV; MacLean N; Brennan S; Hyer ML; Berger A; Traore T; Milhollen M; Smith AC; Minden MD; Pai EF; Hakem R; Schimmer AD
Leukemia; 2019 Jan; 33(1):37-51. PubMed ID: 29884901
[TBL] [Abstract][Full Text] [Related]
2. GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death.
Liu G; Yu J; Wu R; Shi L; Zhang X; Zhang W; Zhong X; Wang Y; Li H; Shen Y; Wu C; Yu R; Niu M; Liu X
Cell Death Dis; 2021 Jul; 12(8):733. PubMed ID: 34301924
[TBL] [Abstract][Full Text] [Related]
3. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.
Murai Y; Jo U; Murai J; Jenkins LM; Huang SN; Chakka S; Chen L; Cheng K; Fukuda S; Takebe N; Pommier Y
Cancer Res; 2021 Jun; 81(11):3067-3078. PubMed ID: 33863777
[TBL] [Abstract][Full Text] [Related]
4. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation.
Baakhlagh S; Kashani B; Zandi Z; Bashash D; Moradkhani M; Nasrollahzadeh A; Yaghmaei M; Mousavi SA; Ghaffari SH
Int Immunopharmacol; 2021 Jan; 90():107202. PubMed ID: 33278749
[TBL] [Abstract][Full Text] [Related]
6. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
Best S; Hashiguchi T; Kittai A; Bruss N; Paiva C; Okada C; Liu T; Berger A; Danilov AV
Blood Adv; 2019 Jan; 3(1):51-62. PubMed ID: 30617217
[TBL] [Abstract][Full Text] [Related]
7. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma.
Xu GW; Ali M; Wood TE; Wong D; Maclean N; Wang X; Gronda M; Skrtic M; Li X; Hurren R; Mao X; Venkatesan M; Beheshti Zavareh R; Ketela T; Reed JC; Rose D; Moffat J; Batey RA; Dhe-Paganon S; Schimmer AD
Blood; 2010 Mar; 115(11):2251-9. PubMed ID: 20075161
[TBL] [Abstract][Full Text] [Related]
8. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.
Hyer ML; Milhollen MA; Ciavarri J; Fleming P; Traore T; Sappal D; Huck J; Shi J; Gavin J; Brownell J; Yang Y; Stringer B; Griffin R; Bruzzese F; Soucy T; Duffy J; Rabino C; Riceberg J; Hoar K; Lublinsky A; Menon S; Sintchak M; Bump N; Pulukuri SM; Langston S; Tirrell S; Kuranda M; Veiby P; Newcomb J; Li P; Wu JT; Powe J; Dick LR; Greenspan P; Galvin K; Manfredi M; Claiborne C; Amidon BS; Bence NF
Nat Med; 2018 Feb; 24(2):186-193. PubMed ID: 29334375
[TBL] [Abstract][Full Text] [Related]
9. A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity.
Barghout SH; Aman A; Nouri K; Blatman Z; Arevalo K; Thomas GE; MacLean N; Hurren R; Ketela T; Saini M; Abohawya M; Kiyota T; Al-Awar R; Schimmer AD
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33476303
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
11. SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia.
Gabellier L; De Toledo M; Chakraborty M; Akl D; Hallal R; Aqrouq M; Buonocore G; Recasens-Zorzo C; Cartron G; Delort A; Piechaczyk M; Tempé D; Bossis G
Haematologica; 2024 Jan; 109(1):98-114. PubMed ID: 37608777
[TBL] [Abstract][Full Text] [Related]
12. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
13. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
15. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Zhuang J; Shirazi F; Singh RK; Kuiatse I; Wang H; Lee HC; Berkova Z; Berger A; Hyer M; Chattopadhyay N; Syed S; Shi JQ; Yu J; Shinde V; Tirrell S; Jones RJ; Wang Z; Davis RE; Orlowski RZ
Blood; 2019 Apr; 133(14):1572-1584. PubMed ID: 30737236
[TBL] [Abstract][Full Text] [Related]
17. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
18. Glucopsychosine increases cytosolic calcium to induce calpain-mediated apoptosis of acute myeloid leukemia cells.
Angka L; Lee EA; Rota SG; Hanlon T; Sukhai M; Minden M; McMillan EM; Quadrilatero J; Spagnuolo PA
Cancer Lett; 2014 Jun; 348(1-2):29-37. PubMed ID: 24631520
[TBL] [Abstract][Full Text] [Related]
19. Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells.
Cornet-Masana JM; Moreno-Martínez D; Lara-Castillo MC; Nomdedeu M; Etxabe A; Tesi N; Pratcorona M; Esteve J; Risueño RM
Oncotarget; 2016 Apr; 7(17):23239-50. PubMed ID: 26992240
[TBL] [Abstract][Full Text] [Related]
20. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
